明星减重药司美格鲁肽生产商、丹麦制药巨头诺和诺德经历了艰难的一年。该公司于去年8月更换领导 层，由马齐亚尔·迈克·杜斯塔德（Maziar Mike Doustdar）接替周赋德（Lars Fruergaard Jorgensen）担任 CEO。 2025年，苏博科获得了高达430万英镑的年度奖金，较2024年的水平增长了约22%。阿斯利康也是伦敦 证交所上市公司中市值最高的企业，最新市值超过3200亿美元。 当地时间2月24日，阿斯利康的一份备案文件显示，该公司CEO苏博科（Pacal Soriot）2025年的薪酬增 至1770万英镑（约合1.64亿元人民币），跻身英国富时100指数中薪酬最高的高管之列。 阿斯利康也是伦敦证交所上市公司中市值最高的企业，最新市值超过3200亿美元（约合2.2万亿元人民 币）。受益于公司强劲的业绩和股价表现，2025年，苏博科获得了高达430万英镑的年度奖金，较2024 年的水平增长约22%。 截至本月，欧洲制药公司高管2025年度年薪陆续披露。近日，瑞士制药巨头诺华披露，该公司首席执行 官万思瀚（Vas Narasimhan）在2025年获得薪酬达2490万瑞士法郎（约合2 ...

Core Insights - The FDA has approved Dupixent (dupilumab) as the first and only treatment for allergic fungal rhinosinusitis (AFRS) in patients aged 6 years and older with a history of sino-nasal surgery, marking a significant advancement in the treatment of this condition [2][3][4] Group 1: Approval and Indications - Dupixent is now approved for treating nine distinct diseases driven by type 2 inflammation, including sino-nasal, skin, gut, and respiratory system diseases [6] - The approval was based on the LIBERTY-AFRS-AIMS phase 3 study, which demonstrated significant improvements in sinus opacification scores and nasal symptoms compared to placebo [4][10] Group 2: Clinical Study Results - In the LIBERTY-AFRS-AIMS study, Dupixent improved sinus opacification scores by 50% compared to 10% for placebo at Week 52, with a significant reduction also observed at Week 24 [4][11] - Patient-reported nasal congestion improved by 67% at Week 24 and 81% at Week 52 compared to 25% and 11% for placebo, respectively [7][13] - Dupixent reduced the risk of systemic corticosteroid use and/or surgery by 92%, with only 3% of patients on Dupixent requiring systemic corticosteroids compared to 31% on placebo [13] Group 3: Safety Profile - The safety profile of Dupixent in the LIBERTY-AFRS-AIMS study was consistent with its known safety profile in chronic rhinosinusitis with nasal polyps (CRSwNP), with common adverse reactions including injection site reactions and conjunctivitis [8][9] Group 4: Market Impact and Future Plans - Dupixent's approval is expected to establish a new standard of care for patients with AFRS, addressing a high unmet need in the treatment landscape [9] - Sanofi and Regeneron plan to submit additional applications to regulatory authorities worldwide to expand access to Dupixent [9][17]

Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study demonstrating Dupixent significantly reduced nasal signs and symptoms and systemic corticosteroid use or surgery compared to placeboAFRS is a chronic type 2 inflammatory disease of the sinuses characterized by an allergic hypersensitivity to fungi, often requiring surgery with high rates of post-operative recurr ...

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery compared to placebo AFRS is a chronic type 2 inflammatory disease of the sinuses characterized by an allergic hypersensitivity to fungi, often requiring surgery with high rates of post-operative recurrence Dupixent is now approved in the U.S. to treat nine distinct diseases driven in part by type 2 inflammation, i ...

【国泰海通医药】春节期间创新药领域重点新闻梳理-海外公司 1）2/12 公司自2019年起任职的CEO PaulHudson不再续聘，前默沙东CEO BelénGarijo上任（#过去3年赛诺菲临床失 败多管线青黄不接）； 2）2/17 赛诺菲&TEVA更新了共同开发的TL1A单抗duvakitug IIb期更长期随访的数据，其中44周时接受900mg药物维 持治疗的UC患者临床缓解率达到58%（较安 【国泰海通医药】春节期间创新药领域重点新闻梳理-海外公司 赛诺菲： 1）2/12 公司自2019年起任职的CEO PaulHudson不再续聘，前默沙东CEO BelénGarijo上任（#过去3年赛诺菲临床失 败多管线青黄不接）； 2）2/17 赛诺菲&TEVA更新了共同开发的TL1A单抗duvakitug IIb期更长期随访的数据，其中44周时接受900mg药物维 持治疗的UC患者临床缓解率达到58%（较安慰剂提高27%），CD患者的内镜应答率达到55%（较安慰剂提高 35%），相比16周均有提高，数据亮眼； 阿斯利康： 1）2/20 FDA批准阿斯利康阿克替尼联合维奈托克全口服、固定疗程方案针对一线CLL ...

Sanofi (NASDAQ:SNY) is among the 7 Oversold Pharma Stocks to Buy Now. Sanofi's (SNY) R&D Track Record Remains Investor Concern, Says BofA Sanofi (NASDAQ:SNY) is one of the most oversold stocks. TheFly reported that on February 20, SNY’s price target was lowered at Citi by EUR 5. On the other hand, earlier on February 12, BofA reduced its price target for SNY from EUR 102 to EUR 92 and downgraded the stock from Buy to Neutral. Following the announcement that Belén Garijo, the former CEO of Merck KGaA, wi ...

Sanofi (NASDAQ:SNY) is one of the Best Dip Stocks to Buy According to Hedge Funds. On February 17, Sanofi (NASDAQ:SNY) announced Manuela Buxo will replace Brian Foard as the Head of its Specialty Care Global Business Unit. Brian Foard, after serving for nearly 9 years, is leaving on February 28 to take on a leadership role elsewhere. ​Manuela Buxo will take over as the Head of Specialty Care Unit on March 1, 2026. She is currently the head of Sanofi’s (NASDAQ:SNY) Global Immunology Alliance Franchise. Fo ...

Core Insights - The biotech industry experienced significant developments this week, including FDA approvals, clinical trial results, and licensing agreements, indicating a dynamic landscape for investment opportunities and advancements in healthcare [1]. FDA Approvals & Rejections - NRx Pharmaceuticals is on track for FDA approval of NRX-100, with existing clinical data and real-world evidence from over 65,000 patients potentially supporting a New Drug Application (NDA) under Fast Track Designation [2][3]. - Kane Biotech received FDA clearance for its Revyve Antimicrobial Skin and Wound Cleanser, which targets wound bacteria and biofilms, with plans for manufacturing scale-up in 2026 [4][5]. - Johnson & Johnson's RYBREVANT FASPRO received FDA approval for a simplified monthly dosing schedule, enhancing treatment options for patients with advanced non-small cell lung cancer [6][7]. - Spruce Biosciences reported positive feedback from FDA Type B meetings for its enzyme replacement therapy for Sanfilippo syndrome type B, with a targeted BLA filing in Q4 2026 [8][9]. - Moderna's seasonal influenza vaccine submission (mRNA-1010) is under FDA review, with a PDUFA date set for August 5, 2026, aiming for availability in the 2026/2027 flu season [10][11]. - Disc Medicine received a Complete Response Letter (CRL) for its NDA for Biopertin in erythropoietic protoporphyria, citing insufficient correlation with sunlight exposure endpoints [13][14]. - AbbVie and Genentech's combination regimen of VENCLEXTA and Acalabrutinib for chronic lymphocytic leukemia (CLL) received FDA approval, showing a 35% reduction in disease progression risk compared to standard treatment [15][16]. Deals - Theriva Biologics entered an exclusive licensing agreement with Rasayana Therapeutics for SYN-020, receiving a $3 million upfront payment and potential milestone payments totaling up to $38 million [17][18]. - Sensei Biotherapeutics acquired Faeth Therapeutics, expanding its oncology portfolio with the investigational asset PIKTOR, and announced a concurrent private placement of $200 million to advance clinical milestones [19][20]. Clinical Trials - Breakthroughs - Eli Lilly's Taltz and Zepbound combination therapy showed positive results in a Phase 3 trial for plaque psoriasis and obesity, achieving superior outcomes compared to Taltz alone [21][22]. - Zealand Pharma reported positive Phase 1a results for ZP9830, a Kv1.3 channel blocker, demonstrating safety and tolerability in healthy volunteers [23][24]. - Novartis' Remibrutinib met primary endpoints in a Phase 3 trial for chronic inducible urticaria, showing significant response rates compared to placebo [26][27]. - Ocular Therapeutix's AXPAXLI demonstrated superiority over aflibercept in a Phase 3 trial for wet age-related macular degeneration, although stock prices fell due to investor disappointment [28][29]. - Rallybio's RLYB116 Phase 1 study showed promising results for immune platelet transfusion refractoriness, with plans for a Phase 2 trial in 2026 [31][32]. - Teva and Sanofi's Duvakitug Phase 2b trial demonstrated durable efficacy in ulcerative colitis and Crohn's disease, reinforcing the rationale for ongoing Phase 3 programs [35][36]. - Genentech's Gazyva met primary endpoints in a Phase III study for primary membranous nephropathy, showing significant remission rates compared to tacrolimus [38][39].

责任编辑：于健 SF069 德克萨斯州检察长办公室发表声明称，赛诺菲设立了向医疗保健提供者提供服务的项目，而这构成了违 反《德克萨斯州医疗保健项目欺诈预防法》的贿赂行为。 赛诺菲在一份声明中表示："这些服务的设置是为了符合相关的联邦和州法律，并且旨在为患者提供帮 助，而非影响医生的处方决策。" 美国德克萨斯州检察长肯·帕克斯顿（Ken Paxton）周四对赛诺菲提起诉讼，指控其该公司"向医疗供应 商行贿，以促使他们优先推荐其药品而非其他替代品"。 "政府的干预与本案的是非曲直无关，赛诺菲正在全力为此次诉讼辩护。"该公司补充道。 德克萨斯州将在此案中寻求超过100万美元的金钱救济，包括民事处罚，以及停止任何进一步非法行为 的禁令。 "政府的干预与本案的是非曲直无关，赛诺菲正在全力为此次诉讼辩护。"该公司补充道。 德克萨斯州将在此案中寻求超过100万美元的金钱救济，包括民事处罚，以及停止任何进一步非法行为 的禁令。 责任编辑：于健 SF069 美国德克萨斯州检察长肯·帕克斯顿（Ken Paxton）周四对赛诺菲提起诉讼，指控其该公司"向医疗供应 商行贿，以促使他们优先推荐其药品而非其他替代品"。 德克萨斯州检察长 ...

Core Viewpoint - Texas Attorney General Ken Paxton has filed a lawsuit against Sanofi, alleging that the company engaged in bribery to encourage healthcare providers to prescribe its medications over alternatives [1]. Group 1: Allegations and Legal Actions - The lawsuit claims that Sanofi created programs that provided services to healthcare providers, which are alleged to constitute bribes in violation of the Texas Health Care Program Fraud Prevention Act [1]. - Attorney General Paxton is seeking over a million dollars in monetary relief, including civil penalties, and an injunction to prevent further unlawful acts by Sanofi [1]. - This is not the first legal action against Sanofi; the Attorney General has previously sued the company for failing to disclose the ineffectiveness of its blood clot prevention drug, Plavix, for certain patients [1]. Group 2: Context of Legal Environment - Last year, Texas also sued Eli Lilly for similar allegations of bribing providers to prescribe its most profitable drugs, including GLP-1 medications Mounjaro and Zepbound [1].